Polatuzumab Vedotin (Pv) Alone Or In-Combination with Obinutuzumab significantly Enhances In-Vitro/In-Vivo Cytotoxicity Against Burkitt Lymphoma (BL)/primary Mediastinal Large B Cell Lymphoma (PMBL)

Authors

Aradhana Awasthi
Dina Edani, New York Medical College
Janet Ayello, New York Medical CollegeFollow
Christian KleinFollow
Mitchell S. Cairo, New York Medical CollegeFollow

Document Type

Abstract

Publication Date

6-2018

Journal Title

Pediatric Blood & Cancer

Department

Pediatrics

Second Department

Health Behavior and Community Health

Recommended Citation

Awasthi, A., Edani, D., Ayello, J., Klein, C., & Cairo, M. S. (2018). Polatuzumab Vedotin (Pv) Alone Or In-Combination with Obinutuzumab significantly Enhances In-Vitro/In-Vivo Cytotoxicity Against Burkitt Lymphoma (BL)/primary Mediastinal Large B Cell Lymphoma (PMBL). Pediatric Blood & Cancer, 65 (Suppl.1), S236. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/192